LivaNova Sees 12.1% Q4 Revenue Growth to $360.9M, Price Target Up to $85
LivaNova’s consensus price target rose to $85 from $69.63 a year ago, while Q4 revenue climbed 12.1% to $360.9 million. Strategic collaboration with Verily on depression biomarkers and presentation at the American Epilepsy Society Annual Meeting underscore innovation focus and support Baird’s $75 target.
1. Analysts Raise Price Targets
Analysts have lifted LivaNova’s consensus price target from $69.63 a year ago to $74.33 three months ago and $85 most recently, reflecting growing confidence in the company’s strategic direction. Robert W. Baird maintains a $75 target, indicating a favorable midrange outlook.
2. Q4 Financial Results
In the fourth quarter, LivaNova generated $360.9 million in revenue, a 12.1% increase year-over-year, and reported U.S. GAAP diluted EPS of $0.56. This performance aligns with the upward trend in analyst estimates and underscores consistent growth across its medical device segments.
3. Strategic Collaboration and Innovation
LivaNova’s partnership with Verily aims to capture clinical biomarkers of depression, enhancing its neuromodulation offerings, while its presentation at the American Epilepsy Society Annual Meeting highlights ongoing advances in epilepsy treatment technologies.